Evidence map›Paper›PMID 31214203›Full record

ReviewFrontiers in immunology2019

Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.

Gregg B Fields

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 136 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Matrix Metalloproteinases on Skin Photoaging.Journal of cosmetic dermatology · 2024
    Review
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gregg B FieldsDepartment of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, FL, United States.
Scripps Research Institute · US

Funding

Mechanism &Inhibition of Collagenolytic ActivityR01CA098799 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FIELDS, GREGG B · 2003 to 2017
$4.5M
Local and systemic control of multiple myeloma colonization and growth by MMP-13R01CA239214 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI LYNCH, CONOR C · 2019 to 2023
$2.2M
New probes for matrix metalloproteinase 13R01AR063795 · NIAMS · TORREY PINES INST FOR MOLECULAR STUDIES · PI FIELDS, GREGG B · 2013 to 2015
$1.5M
NCI NIH HHS R01 CA098799NCI NIH HHS R01 CA239214NIAMS NIH HHS R01 AR063795
6 · The paper itself

Abstract

Angiogenesis is facilitated by the proteolytic activities of members of the matrix metalloproteinase (MMP) family. More specifically, MMP-9 and MT1-MMP directly regulate angiogenesis, while several studies indicate a role for MMP-2 as well. The correlation of MMP activity to tumor angiogenesis has instigated numerous drug development programs. However, broad-based and Zn

Indexed as

AnimalsAntineoplastic AgentsDrug DevelopmentHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMolecular Targeted TherapyNeoplasmsNeovascularization, PathologicProtein Interaction Domains and MotifsStructure-Activity RelationshipAntineoplastic AgentsMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMatrix Metalloproteinasesangiogenesisantibodycancerclinical trialexositemetalloproteinaseprotease inhibitor

Identifiers

PMID31214203
PMCPMC6558196
OpenAlexW2948660510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.